Overview

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This trial will look at 2 different drug combinations that have well known safety profiles and are known to be active against non small cell lung cancer and combine them with bevacizumab, an experimental drug that has shown effectiveness when added to other drug combinations for advanced non-small cell lung cancer. The primary objective in this study is to see how well this combination of drugs keeps the cancer from getting worse in this elderly population of non-small cell lung cancer patients.
Phase:
Phase 2
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborators:
Eli Lilly and Company
Genentech, Inc.
Treatments:
Bevacizumab
Carboplatin
Gemcitabine
Pemetrexed